natgillin/translations-raw huggingface dataset:
• Co-administration with medicines that are highly dependent on CYP3A4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as orally administered midazolam and triazolam, bepridil, pimozide, lurasidone, lumefantrine, halofantrine, tyrosine kinase inhibitors, simvastatin, lovastatin, quetiapine, alfuzosin, silodosin, and ergot derivatives (dihydroergotamine, ergonovine, ergotamine, 
• Sočasna uporaba zdravil, katerih očistek je zelo odvisen od CYP3A4/5 in pri katerih je zvišana koncentracija v plazmi povezana z resnimi in/ali življenjsko nevarnimi učinki; takšna zdravila so npr. peroralno uporabljeni midazolam in triazolam, bepridil, pimozid, lurasidon, lumefantrin, halofantrin, zaviralci tirozin-kinaze, simvastatin, lovastatin, kvetiapin, alfuzosin, silodozin in derivati ergot alkaloidov (dihidroergotamin, ergonovin, ergotamin, metilergonovin) (glejte
The addition of Victrelis to peginterferon alfa-2b and ribavirin was associated to higher incidences of increase in uric acid, triglycerides and cholesterol total compared to peginterferon alfa-2b and 
Dodatek zdravila Victrelis k peginterferonu alfa-2b in ribavirinu je bil povezan z večjo pojavnostjo povečanih koncentracij sečne kisline, trigliceridov in celokupnega holesterola, v primerjavi z zdravljenjem s samo peginterferonom alfa-2b in ribavirinom.
The median times for the most relevant boceprevir-resistant variants observed in genotype 1a patients (> 10%) to become undetectable were as follows: R155K+V36M, 0.69 years; V36M, 0.89 years; R155K+T54S, 1.05 years; R155K, 1.08 years; and T54S, 1.14 years. 
Mediani časi, da so nezaznavne postale najpomembnejše na boceprevir odporne variante, so bili pri bolnikih, okuženih z genotipom 1a (>10 %), naslednji: R155K+V36M - 0,69 let, V36M - 0,89 let, R155K+T54S - 1,05 let, R155K - 1,08 let in T54S - 1,14 let.
The activity of boceprevir against the HCV genotype 1b replicon was reduced (2- to 8-fold) by the following amino acid substitutions in the NS3 protease domain: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M and M175L. 
Učinkovitost boceprevirja proti replikacijski enoti HCV genotipa 1b se je zmanjšala (za 2- do 8-krat) ob naslednjih zamenjavah aminokislin na NS3 domeni proteaze: V36A/M, F43S, T54A/G/S, V55A, R155K/G, V158I, V170M in M175L.
There is potential for inhibitors of these transporters to increase concentrations of boceprevir; the clinical implications of these interactions are not known. 
Zaviralci teh transporterjev lahko povečajo koncentracije boceprevirja.
The race distribution of subjects was as follows: 82% White, 18% Non-White, 14% Black, 3% Asian, and 1% Multiracial. 
Porazdelitev preiskovancev po rasah je bila naslednja: 82 % belcev, 18 % ne-belcev, 14 % črncev, 3 % Azijcev, 1 % večrasnih.
Overall, the presence of baseline RAVs did not appear to have a notable association with treatment response in subjects receiving the combination of boceprevir with peginterferon alfa-2b and ribavirin. 
Prisotnost RAV na začetku zdravljenja, kot kaže, ni bila občutno povezana z odzivom na zdravljenje pri preiskovancih, ki so prejemali boceprevir ter peginterferon alfa-2b in ribavirin.
The race distribution of subjects was as follows: 82% White, 14% Black, 2% Asian, 1% multiracial, 1% American Indian or Alaskan Native. 
Porazdelitev preiskovancev po rasah je bila naslednja: 82 % belcev, 14 % črncev, 2 % Azijcev, 1 % večrasnih, 1 % ameriških Indijancev ali aljaških domorodcev.
UAB Merck Sharp & Dohme Tel.: +370 5 278 02 47 msd_lietuva@merck.com 
UAB Merck Sharp & Dohme Tel.: +370 5 278 02 47 msd_lietuva@merck.com info-msdbg@merck.com
Glomerular filtration rate decreased * Includes adverse reactions which may be serious as assessed by the investigator in clinical trial 
Preiskave zmanjšanje telesne mase šum na srcu, povečana srčna frekvenca zmanjšana hitrost glomerulne filtracije * Vključuje neželene učinke, ki so po oceni raziskovalca pri preiskovancih v kliničnem preskušanju
• are taking bepridil, pimozide, lurasidone, oral midazolam, oral triazolam, simvastatin, lovastatin, alfuzosin, silodosin, 'ergot' type medicines (such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine), lumefantrine, halofantrine, quetiapine, or tyrosine kinase inhibitors. 
• če jemljete bepridil, pimozid, lurasidon, peroralni midazolam, peroralni triazolam, simvastatin, lovastatin, alfuzosin, silodozin, zdravila ergotskega tipa (npr. dihidroergotamin, ergonovin, ergotamin ali metilergonovin), lumefantrin, halofantrin, kvetiapin ali zaviralce tirozin-kinaze.
Hepatobiliary disorders Uncommon: 
Bolezni imunskega sistema Redki:
Dose adjustments of cyclosporine should be anticipated when administered with Victrelis and should be guided by close monitoring of cyclosporine blood concentrations, and frequent assessments of renal function and cyclosporine-related side effects. 
Prilagoditi ga je treba na podlagi natančnega nadzora koncentracije ciklosporina v krvi in pogostih ocen ledvične funkcije ter s ciklosporinom povezanih neželenih učinkov.
Skin and subcutaneous tissue disorders Very common: 
Bolezni dihal, prsnega koša in mediastinalnega prostora Zelo pogosti:
Subjects who were not able to enrol in this study within 2 weeks received PR for 4 weeks followed by Victrelis 800 mg three times daily + PR for 44 weeks. 
Preiskovanci, vključeni v študijo PROVIDE v dveh tednih po prejetju zadnjega odmerka PR v začetni študiji, so 44 tednov prejemali zdravilo Victrelis 800 mg trikrat na dan + PR. Preiskovanci, ki niso mogli biti vključeni v to študijo v dveh tednih, so 4 tedne prejemali PR in nato 44 tednov zdravilo Victrelis 800 mg trikrat na dan + PR.
Tacrolimus* (tacrolimus 0.5 mg single dose + Victrelis 800 mg single dose) 
Takrolimus* (takrolimus 0,5 mg enkratni odmerek + zdravilo Victrelis 800 mg enkratni odmerek).
Decreased appetite* Dehydration*, hyperglycaemia*, hypertriglyceridaemia, 
dehidracija*, hiperglikemija*, hipertrigliceridemija, hiperurikemija
What Victrelis looks like and contents of the pack The hard capsules have a yellowish-brown cap with the "MSD" logo printed in red ink and an offwhite body with "314" printed in red ink. 
Zgornji del trde kapsule je rumenkasto-rjav in ima z rdečim črnilom natisnjeno oznako "MSD", spodnji del kapsule pa je sivo bel in ima z rdečim črnilom natisnjeno kodo "314".
Anaemia was observed in 49% of subjects treated with the combination of Victrelis with peginterferon alfa-2b and ribavirin compared with 29% of subjects treated with peginterferon alfa-2b and ribavirin alone. 
Anemijo so opazili pri 49 % preiskovancev, ki so prejemali zdravilo Victrelis v kombinaciji s peginterferonom alfa-2b in ribavirinom, in pri 29 % preiskovancev, zdravljenih samo s peginterferonom alfa-2b in ribavirinom.
Patients who have failed previous therapy: previous partial responders and relapsers to interferon and 
Bolniki, pri katerih predhodno zdravljenje ni bilo uspešno: tisti, ki so se delno odzvali na predhodno zdravljenje, in tisti, ki se jim je bolezen po zdravljenju z interferonom in ribavirinom ponovila
In boceprevir-treated subjects who did not attain sustained virologic response (SVR) for whom samples were analysed, 53% had post 
Med preiskovanci, ki so prejemali boceprevir in niso dosegli trajnega virološkega odziva (SVR), a so imeli opravljeno analizo vzorcev, jih je imelo RAV v obdobju po začetku
Caution should be exercised when boceprevir is combined with ketoconazole or azole antifungals (itraconazole, posaconazole, voriconazole). 
Pri uporabi kombinacij boceprevirja s ketokonazolom oz. azolnimi antimikotiki (itrakonazolom, posakonazolom, vorikonazolom) je potrebna previdnost.
The distribution of subjects by genders was 37% men and 63% women. 
Porazdelitev preiskovancev po spolu je bila: 37 % moških in 63 % žensk.
To obtain the hard capsules the foil of the blister should be peeled off. Victrelis is to be taken orally with food (a meal or light snack). 
Zdravilo Victrelis se jemlje peroralno s hrano (obrok ali lahek prigrizek).
Fifty-seven percent (208/368) of subjects in the Victrelis-RGT arm and 56% (204/366) of subjects in the Victrelis-PR48 arm had undetectable HCV-RNA at TW 8 compared with 17% (60/363) of 
in 56 % (204/366) preiskovancev iz skupine Victrelis-PR48 je imelo 8.
Goitre, hypothyroidism Hyperthyroidism 
golša, hipotiroidizem
All subjects with detectable HCV-RNA in plasma at TW 24 were discontinued from treatment. 
TZ zaznavno HCV-RNA v plazmi, je bilo zdravljenje prekinjeno.
(effect on P-gp transport in the 
(učinek na prenos s pomočjo P
Platelet counts were decreased for subjects in the Victrelis containing-arms (3%) compared to subjects receiving peginterferon alfa-2b and ribavirin alone (1%). 
Število trombocitov se je zmanjšalo pri preiskovancih v skupinah z zdravilom Victrelis (3 %) v primerjavi s preiskovanci, ki so prejemali samo peginterferon alfa-2b in ribavirin (1 %).
No dose adjustment of dabigatran is recommended. 
Prilagoditve odmerka dabigatrana ne priporočamo.
- if you are a man who is taking ribavirin: do not have sex with a pregnant woman unless you use a condom. 
Spolnih odnosov z nosečo žensko ne smete imeti brez uporabe kondoma.
The median time for all RAVs to become undetectable was 1.17 years for genotype 1a. 
Pri genotipu 1a je bil mediani čas, da so postale nezaznavne vse RAV, 1,17 let.
How to store Victrelis 
Shranjevanje zdravila Victrelis
Lopinavir/Ritonavir* (lopinavir 400 mg / ritonavir 100 mg two times daily + Victrelis 800 mg three times daily) 
Darunavir/ritonavir* (darunavir 600 mg / ritonavir 100 mg dvakrat na dan + zdravilo Victrelis 800 mg trikrat na dan)
Victrelis is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy (see sections 4.4 and 5.1). 
Zdravilo Victrelis je indicirano za zdravljenje kronične okužbe s hepatitisom C genotipa 1 v kombinaciji s peginterferonom alfa in ribavirinom pri odraslih bolnikih s kompenzirano jetrno boleznijo, ki še niso bili zdravljeni ali pri njih predhodno zdravljenje ni bilo uspešno (glejte
Infections and infestations Common: 
Motnje reprodukcije in dojk Pogosti:
SVR rates with "missing=failure" approach were nearly identical to those in the table: 37% for Control, 62% for 
TS. Deleži SVR s pristopom "manjkajoči = neuspeh" so bili skoraj enaki tistim v preglednici: 37 % v kontrolni skupini, 62 % v skupini Victrelis-RGT, 65 % v skupini Victrelis-PR48.
A secondary analysis of subjects who received at least one dose of Victrelis or placebo after the four week lead-in with peginterferon alfa-2b and ribavirin (Modified-Intent-to-Treat population) demonstrated SVR rates of 61% to 67% in the Victreliscontaining arms compared to 22% PR48 control. 
Sekundarna analiza preiskovancev, ki so prejeli vsaj en odmerek zdravila Victrelis ali placeba po štirih tednih uvajalnega obdobja s peginterferonom alfa-2b in ribavirinom (Modified Intent to Treat population), je pokazala v skupinah, zdravljenih z zdravilom Victrelis, delež SVR 61 % do 67 % ter 22 % v kontroli PR48.
Victrelis must be administered in combination with peginterferon alfa and ribavirin. 
Zdravilo Victrelis je treba uporabiti v kombinaciji s peginterferonom alfa in ribavirinom.
The proportion of subjects who received a transfusion for the management of anaemia was 3% of subjects in the Victrelis-containing arms compared to < 1% of subjects receiving peginterferon alfa-2b and ribavirin alone. 
Delež preiskovancev, ki so prejeli transfuzijo za obvladovanje anemije, je bil v skupinah z zdravilom Victrelis 3 %, med preiskovanci, ki so prejemali samo peginterferon alfa-2b in ribavirin, pa < 1 %.
Exposure to atorvastatin was increased when administered with Victrelis. 
Izpostavljenost atorvastatinu se je povečala pri sočasni uporabi zdravila Victrelis.
No dose adjustment is necessary when coadministered with Victrelis. 
Prilagoditev odmerka pri sočasni uporabi z zdravilom Victrelis ni potrebna.
The addition of Victrelis to peginterferon alfa-2b and ribavirin significantly increased the SVR rates compared to peginterferon alfa-2b and ribavirin alone in the combined cohort (63% to 66% Victreliscontaining arms vs. 38% PR48 control) for randomized subjects who received at least one dose of any study medicine (Full-Analysis-Set population) and decreased the length of therapy to 28 weeks for early responders (see Table 4). 
Dodatek zdravila Victrelis peginterferonu alfa-2b in ribavirinu je v kombinirani kohorti pri randomiziranih preiskovancih, ki so prejeli vsaj en odmerek kateregakoli raziskovanega zdravila (Full Analysis Set population), značilno povečal delež SVR v primerjavi s kombinacijo peginterferona alfa2b in ribavirina samo (63 % do 66 % v skupinah bolnikov z zdravilom Victrelis v primerjavi z 38 % v kontrolni skupini PR48) ter je pri preiskovancih z zgodnjim odzivom skrajšal trajanje zdravljenja na 28 tednov (glejte preglednico 4).
Eyes or ears: pink eye; eye pain; deafness; trouble hearing; swelling around the eyelid; increased tearing; fluid draining from the ear or eye; abnormal feeling around the eye, red patch on the white of the eye; yellowing of the white part of the eyes or of the skin Mouth, nose or throat: hoarseness, dry throat or lips; painful or bleeding gums; sensitive tooth or toothache; tongue swollen, discoloured, or has sores; blistering by the tongue; severe pain when swallowing; chest pain close to the lungs; chest pain worsens when taking a deep breath; uncontrolled salivating; overactive thyroid gland Skin and hair: hives; open sore; intolerance to heat; markedly red face; pale face; yellow skin; rash due to sunlight; wound not healing normally Feet or hands or legs or arms: sensation of pain, numbness, tingling or prickling; blood clot in a vein; feeling cold in an arm or leg; painful inflammation of the joints most commonly in the foot (gout) 
Oči in ušesa: pordelo oko, bolečine v očeh, gluhost, naglušnost, oteklost okrog vek, močnejše solzenje, tekoč izcedek iz ušesa ali očesa, nenormalen občutek okrog očesa, rdeče lise na očesni beločnici, porumenelost očesne beločnice ali kože Usta, nos in žrelo: hripavost, suho žrelo ali ustnice, boleče ali krvaveče dlesni, občutljivost zob ali zobobol, oteklost jezika, spremenjena barva jezika ali razjede na jeziku, mehurji na jeziku, huda bolečina pri požiranju, bolečina v prsnem košu blizu pljuč, bolečina v prsnem košu, ki se poslabša ob globokem vdihu, nekontrolirano slinjenje, prekomerno delovanje ščitnice Koža, lasje in dlake: koprivnica, odprta razjeda, neprenašanje vročine, izrazito rdeč obraz, bled obraz, porumenelost kože, izpuščaj zaradi sončne svetlobe, rana, ki se ne celi normalno Stopala, dlani, noge ali roke: bolečina, omrtvičenost, mravljinčenje ali zbadanje, krvni strdek v veni, občutek hladu v roki ali nogi, boleče vnetje sklepov, najpogosteje na stopalu (putika)
ethinyl estradiol AUC ↓ 26% ethinyl estradiol Cmax ↓ 21% 
etinilestradiol AUC ↓ 26 % etinilestradiol Cmax ↓ 21 %
The safety and efficacy of Victrelis alone or in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C genotype 1 infection has not been studied in patients who have failed previous therapy with Victrelis or other HCV protease inhibitors. 
Varnost in učinkovitost zdravila Victrelis samega ali v kombinaciji s peginterferonom alfa in ribavirinom za zdravljenje okužbe s kroničnim hepatitisom C genotipa 1 nista raziskani pri bolnikih, pri katerih predhodno zdravljenje z zdravilom Victrelis ali drugimi zaviralci proteaze HCV ni bilo uspešno.
The distribution of subjects by gender was 67% men and 33% women. 
Porazdelitev preiskovancev po spolu je bila 67 % moških in 33 % žensk.
Neutropenia 
Odpornost
A randomized, parallel-arm, open-label study (P06086) was conducted to compare two strategies for the management of anaemia (use of erythropoietin versus ribavirin dose reduction) in 687 subjects including 60 cirrhotic patients with previously untreated CHC genotype 1 infection who became anaemic during therapy with Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600 1,400 mg 
Za primerjavo dveh načinov obvladovanja anemije (uporaba eritropoetina v primerjavi z zmanjšanjem odmerka ribavirina) so izvedli randomizirano, odprto študijo z vzporedno skupino (P06086) pri 687 preiskovancih, vključno s šestdesetimi bolniki s cirozo, s predhodno nezdravljeno okužbo s CHC genotipa 1, ki so med zdravljenjem z zdravilom Victrelis 800 mg peroralno trikrat na dan v kombinaciji s PR [peginterferon alfa-2b 1,5 µg/kg/teden subkutano in ribavirin odvisno od telesne mase (600 - 1.400 mg dvakrat na dan) peroralno, razdeljeno v dva odmerka], postali anemični.
The race distribution of subjects was as follows: 84% white, 13% Black, 2% Asian, and 1% others. 
Porazdelitev preiskovancev po rasah je bila: 84 % belcev, 13 % črncev, 2 % Azijcev in 1 % drugih.
In subjects who demonstrated interferon responsiveness by TW 4, treatment with the combination of Victrelis with peginterferon alfa-2b and ribavirin resulted in SVR rates of 79-81%, compared to 51% in subjects treated with standard of care. 
TZ, je zdravljenje s kombinacijo zdravila Victrelis ter peginterferona alfa-2b in ribavirina povzročilo delež SVR od 79 do 81 %, v primerjavi z 51 % pri preiskovancih, zdravljenih s standardnim zdravljenjem.
Heart or circulation: fast or uneven heart-beat; high or low blood pressure Blood: drop in the number of blood platelets - the signs may include bleeding or bruising more easily than usual; high sugar (glucose) levels in the blood; high triglycerides levels in the blood; high uric acid levels in the blood; a combination of low platelet, red and white blood cell counts (pancytopenia); a severe drop of neutrophil count (agranulocytosis) 
Prsni koš: težko dihanje, nelagodje v prsnem košu, bolečina v prsnem košu, občutek teže v prsnem košu s težkim dihanjem ali piskajočim dihanjem Srce in obtočila: hitro ali neredno bitje srca, visok ali nizek krvni tlak Kri: zmanjšanje števila trombocitov - med znaki so lahko krvavitve ali hitrejše pojavljanje modric kot po navadi, visoka vrednost sladkorja (glukoze) v krvi, visoka vrednost trigliceridov v krvi, visoka vrednost sečne kisline v krvi, kombinacija majhnega števila trombocitov, rdečih in belih krvnih celic (pancitopenija), močno zmanjšano število nevtrofilcev (agranulocitoza)
Victrelis in combination with ribavirin and peginterferon alfa is contraindicated in women who are 
Zdravilo Victrelis v kombinaciji z ribavirinom in peginterferonom alfa je kontraindicirano pri
Patients who failed previous therapy: prior null responders, partial responders and relapsers to 
Bolniki, pri katerih predhodno zdravljenje ni bilo uspešno: na predhodno zdravljenje z interferonom in ribavirinom popolnoma neodzivni bolniki, delno odzivni bolniki in bolniki z recidivom
- if you are a woman of childbearing age who is taking ribavirin: you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped. 
Pri vas mora biti nosečnostni test negativen pred zdravljenjem, vsak mesec med zdravljenjem in še 4 mesece po zaključku zdravljenja.
No dose adjustment of digoxin or Victrelis is recommended. 
Prilagoditev odmerka digoksina ali zdravila Victrelis ni potrebna.
**** Partial Responder: subject who failed to achieve SVR after at least 12 weeks of previous treatment with peginterferon alfa-2b and ribavirin, but demonstrated a ≥ 2 log10 reduction in HCVRNA by Week 12 and had detectable HCV-RNA at End of Treatment (EOT). 
****Delno odzivni bolnik: preiskovanec, pri katerem po najmanj 12 tednih predhodnega zdravljenja s peginterferonom alfa-2b in ribavirinom ni bil dosežen SVR, je pa do 12. tedna bilo doseženo ≥ 2 log10 zmanjšanje HCV-RNA, in je ob koncu zdravljenja (KZ) imel zaznavno HCV-RNA.
Eleven subjects were missing TW 4 assessment (HCV-RNA) and were not included in the Lead-In 
TZ manjkajoče izvide (HCV-RNA) in niso bili vključeni v rezultate
In C/C patients receiving tritherapy 89% in treatment naive were HCV-RNA undetectable by TW 8 and eligible for shorter duration of therapy as compared to 52% in treatment naïve non C/C. 
TZ in zato možnost za krajše zdravljenje 89 % predhodno nezdravljenih bolnikov , v primerjavi z 52 % ne-C/C še ne zdravljenih bolnikov.
A secondary analysis of subjects who received at least one dose of Victrelis or placebo after the four-week lead-in with peginterferon alfa-2b and ribavirin (ModifiedIntent-to-Treat population) demonstrated SVR rates in the combined cohort of 67% to 68% Victreliscontaining arms vs. 40% PR48 control. 
Sekundarna analiza preiskovancev, ki so po štiri-tedenskem obdobju uvajanja s peginterferonom alfa-2b in ribavirinom prejeli vsaj en odmerek zdravila Victrelis ali placeba (Modified-Intent-to-Treat population), je pokazala v kombinirani kohorti z zdravilom Victrelis delež SVR od 67 % do 68 %, v kontrolni skupini PR48 pa 40 %.
RESPOND-2 (P05101) was a randomized, parallel-group, double-blinded study comparing two therapeutic regimens of Victrelis 800 mg orally three times daily in combination with PR [peginterferon alfa-2b 1.5 µg/kg/week subcutaneously and weight-based ribavirin (600 1,400 mg BID) orally divided twice daily] compared to PR alone in adult subjects with chronic hepatitis C HCV genotype 1 infection with demonstrated interferon responsiveness (as defined historically by a decrease in HCV-RNA viral load ≥ 2 log10 by Week 12 or undetectable HCV-RNA at end of prior treatment with a subsequent detectable HCV-RNA in plasma) and who failed prior treatment with peginterferon alfa and ribavirin. 
Študija RESPOND-2 (P05101) je bila randomizirana, dvojno slepa študija vzporednih skupin, ki je primerjala dva režima zdravljenja z 800 mg zdravila Victrelis peroralno trikrat na dan v kombinaciji s PR [peginterferon alfa-2b 1,5 µg/kg/teden subkutano in ribavirin na podlagi telesne mase (600 1.400 mg dvakrat na dan) peroralno razdeljeno v dva dnevna odmerka] in samo PR pri odraslih preiskovancih z okužbo s kroničnim hepatitisom C HCV genotipa 1 ter dokazano odzivnostjo na interferon (v anamnezi opredeljeno z ≥ 2 log10 zmanjšanjem virusnega bremena HCV-RNA do 12. tedna ali nezaznavno HCV-RNA na koncu prejšnjega zdravljenja in s pozneje zaznavno HCVRNA v plazmi), pri katerih predhodno zdravljenje s peginterferonom alfa-2b in ribavirinom ni bilo uspešno.
No dose adjustment required for Victrelis or raltegravir. 
Prilagoditev odmerka zdravila Victrelis ali raltegravirja ni potrebna.
Table 8 presents sustained virologic response per treatment arm in patients who had failed previous therapy that were early responders and late responders and that received similar therapy up to 
Preglednica 8 prikazuje trajen virološki odziv v posameznih skupinah pri bolnikih, pri katerih predhodno zdravljenje ni bilo uspešno, z zgodnjim odzivom ali s poznim odzivom, ki so prejemali
Among the 314 subjects, 230 were infected with genotype 1a HCV and 84 were infected with genotype 1b HCV. Seventy percent (70%) (162/230) of genotype 1a subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing. 
Med 314 preiskovanci je bilo 230 okuženih s HCV genotipa 1a in 84 s HCV genotipa 1b.
General: light-headedness, arthritis; increased tendency to bleed; swollen glands in neck or armpit or groin; intense burning or stabbing pain; increased sensitivity to light, sound, what is felt, or food one tastes; diabetes 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) Splošno: omotičnost, artritis, povečana nagnjenost h krvavitvam, otekle bezgavke na vratu, v pazduhah ali dimljah, izrazita pekoča ali zbadajoča bolečina, večja občutljivost za svetlobo, zvok, dotike ali okuse hrane, sladkorna bolezen